MyFinsight
Home
Blog
About
Back
Cash Flow
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)
source: myfinsight.com
Proceeds from 2026 april
registered direct...
$2,271,858
Proceeds from issuance of
common stock in...
$839,667
(37.59%↑ Y/Y)
Net cash provided by
financing activities
$3,111,525
(-48.82%↓ Y/Y)
Net increase in cash
$1,401,573
(-40.55%↓ Y/Y)
Canceled cashflow
$1,709,952
Accounts payable and
accrued expenses
$305,937
(228.44%↑ Y/Y)
Share-based compensation
$200,537
(-69.51%↓ Y/Y)
Share-based payments to
vendors
$80,999
(-58.73%↓ Y/Y)
Net cash used in
operating activities
-$1,709,952
(54.06%↑ Y/Y)
Canceled cashflow
$587,473
Net loss
-$2,254,173
(48.72%↑ Y/Y)
Other receivable
$38,994
(457.12%↑ Y/Y)
Prepaid expenses
$4,258
(109.14%↑ Y/Y)
Back